Impact Factor 3.519

Frontiers journals are at the top of citation and impact metrics

This article is part of the Research Topic

Endocrine Disrupters and Metabolism

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2018.00684

Analysis of lipid metabolism, immune function and neurobehavior in adult C57BL/6JxFVB mice after developmental exposure to di (2-ethylhexyl) phthalate

 Liana Bastos Sales1, Joantine van Esterik2, Hennie Hodemaekers3,  Marja Lamoree1, Timo Hamers1, Leo van der Ven3 and  Juliette Legler4, 5*
  • 1Department of Environment and Health, Faculty of Science, VU University Amsterdam, Netherlands
  • 2Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Netherlands
  • 3National Institute for Public Health and the Environment, Netherlands
  • 4Endocrine Toxicology, Institute for Risk Assessment Sciences, Utrecht University, Netherlands
  • 5Utrecht Institute for Pharmaceutical Sciences, Netherlands

Background: Developmental exposure to di (2-ethylhexyl) phthalate (DEHP) has been implicated in the onset of metabolic syndrome later in life. Alterations in neurobehavior and immune functions are also affected by phthalate exposure and may be linked to the metabolic changes caused by developmental exposure to DEHP. Objectives: Our goal was to study the effects of developmental exposure to DEHP in the context of metabolic syndrome by integrating different parameters to assess metabolic, neurobehavioral and immune functions in one model. Methods: Female C57BL/6J mice were exposed to DEHP through the diet during gestation and lactation at doses ranging from 3.3 to 100000 µg/kg body weight/day (µkd). During a 1-year follow-up period, a wide set of metabolic parameters was assessed in the F1 offspring, including weekly body weight measurements, food consumption, physical activity, glucose homeostasis, serum lipids and endocrine profile. In addition, neurobehavioral and immune functions were assessed by sweet preference test, object recognition test, acute phase protein and cytokines production. Animals were challenged with a high fat diet (HFD) in the last 9 weeks of the study. Results: Increased free fatty acids (FFA) and, high density lipoprotein (HDL-C) were observed in serum, together with a decrease in glycated haemoglobin levels in blood of 1-year old male DEHP-exposed offspring after HFD challenge. For the most sensitive endpoint measured (FFA), a lower bound of the 90%-confidence interval for benchmark dose (BMD) at a critical effect size of 5% (BMDL) of 2160 µkd was calculated. No persistent changes in body weight or fat mass were observed. At 33000 µkd altered performance was found in the object recognition test in males and changes in interferon (IFN)γ production were observed in females. Conclusions: Developmental exposure to DEHP combined with HFD in adulthood led to changes in lipid metabolism and neurobehavior in male offspring and cytokine production in female offspring. Our findings contribute to the evidence that DEHP is a developmental dyslipidemic chemical, however more research is needed to further characterize adverse health outcomes and the mechanisms of action associated with the observed sex-specific effects.

Keywords: early-life exposure, Phthalate, DEHP, Lipid Metabolism, endocrine disruption, neurobehavior, Immunofunction, sex-specificity, mouse model, Developmental exposure and adult disease

Received: 18 Jul 2018; Accepted: 01 Nov 2018.

Edited by:

Angel Nadal, Universidad Miguel Hernández de Elche, Spain

Reviewed by:

Andrea C. Gore, University of Texas at Austin, United States
Juan Martinez-Pinna, University of Alicante, Spain  

Copyright: © 2018 Bastos Sales, van Esterik, Hodemaekers, Lamoree, Hamers, van der Ven and Legler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Juliette Legler, Endocrine Toxicology, Institute for Risk Assessment Sciences, Utrecht University, Utrect, 3584 CL, Netherlands, j.legler@uu.nl